Stereotactic Radiotherapy for Oligoprogressive ER+/HER- Metastatic Breast Cancer, a Prospective Phase 2 Study (Oligopro-Breast)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The Oligopro-Breast trial is a Phase II study targeting women with ER+/HER2- metastatic breast cancer who have been on endocrine therapy and/or CDK4/6 inhibitors for at least 6 months, and show progressive disease at 1-3 extracranial metastases, which are treatable locally. The trial aims to investigate if treating these resistant metastases with SBRT (or other local treatments if SBRT is not possible) can extend the use of the current systemic therapy. Patients will continue their existing systemic treatment while receiving SBRT on all progressive lesions. If new oligoprogression occurs, SBRT will be performed again. A new systemic treatment line will start if there is polyprogression (more than 3 lesions at once), progression of more than 6 lesions over 12 months, intracranial progression, or lesions that cannot be treated locally. The scientific question is whether local treatment of resistant metastases can prolong the effectiveness of ongoing systemic therapy, which is particularly beneficial if the treatment is well-tolerated. The primary objective is to measure the proportion of patients surviving without changing their systemic treatment line at 6 months after SBRT. This trial is significant for patients as it explores a method to potentially extend the duration of effective and well-tolerated treatments, offering hope for better management of metastatic breast cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Ogólny stan zdrowia pozwalający na umiarkowaną aktywność (skala 0-2).
- •Rak piersi przerzutowy z potwierdzonymi cechami ER+ i HER2-.
- •Przerzuty ograniczone do 1-3 ognisk poza mózgiem, które można skutecznie leczyć miejscowo.
- •Leczenie systemowe (hormonalne i/lub blokery CDK4/6) trwało co najmniej 6 miesięcy przed pojawieniem się progresji.
- •Pacjentka będzie kontynuować obecne leczenie systemowe.
✗ Disqualifies
- •Inny nowotwór, który nie jest w całkowitej remisji.
- •Wcześniejsze miejscowe leczenie tej samej progresji w ramach obecnego leczenia systemowego.
- •Aktualna progresja w ognisku, które było wcześniej leczone promieniowaniem i nie nadaje się do operacji lub ablacji.
- •Przerzuty do mózgu (chyba że są nieaktywne od co najmniej 6 miesięcy).
- •Ciąża.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- February 2, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (5)
Jules Bordet Institute
Brussels, Belgium
UZ Gent
Ghent, Belgium
AZ Groeninge
Kortrijk, Belgium
AZ Sint-Maarten
Mechelen, Belgium
CHU UCL Namur - Site Saint Elisabeth
Namur, Belgium
Trial contact
Robbe Van den Begin, MD PhD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.